Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Cancer J. 2012 May-Jun;18(3):268-74. doi: 10.1097/PPO.0b013e318258b743.
Lung cancer-related mortality is the most common cause of cancer death worldwide. Detecting lung cancer at an earlier stage and, ideally, predicting who will develop the disease and particularly the most aggressive forms of cancer are the biggest challenge. MicroRNAs (miRNAs) are short, noncoding RNA molecules with regulatory function on protein-coding genes. Because of their fundamental role in development and differentiation, their involvement in the biological mechanisms underlying tumorigenesis, as well as their low complexity, stability, and easy detection, they represent a promising class of tissue- and blood-based biomarkers of cancer. We summarize the current literature on the use of microRNAs as diagnostic and prognostic tools in lung cancer and discuss the relevant clinical implications of these findings.
肺癌相关死亡率是全球癌症死亡的最常见原因。更早地发现肺癌，理想情况下预测哪些人将患上癌症，特别是最具侵袭性的癌症形式，是最大的挑战。microRNAs（miRNAs）是具有调节功能的短链非编码 RNA 分子，可调节蛋白质编码基因的表达。由于它们在发育和分化中的重要作用，以及它们在肿瘤发生的生物学机制中的参与，以及它们的低复杂性、稳定性和易于检测，它们代表了一类有前途的基于组织和血液的癌症生物标志物。我们总结了目前关于 microRNAs 作为肺癌诊断和预后工具的文献，并讨论了这些发现的相关临床意义。
